Proteasome Inhibitors

01/15/2023 - "For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. "
01/01/2020 - "The introduction of proteasome inhibitors and immunomodulatory and antibody drugs has dramatically improved the prognosis of multiple myeloma (MM) in the 21st century. "
01/01/2019 - "Proteasome inhibitors (PIs) have markedly improved response rates as well as the survival of multiple myeloma (MM) patients over the past decade and have become an important foundation in the treatment of MM patients. "
01/01/2018 - "In particular, proteasome inhibitors have become very important agents for treating multiple myeloma and very useful tools in basic research. "
06/01/2021 - "Proteasome inhibitors, novel agents, have significantly improved survival rates among multiple myeloma patients. "

01/03/2020 - "This approach could expand the repertoire of cancer types that can be successfully treated with proteasome inhibitors in the clinic."
01/01/2017 - "Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. "
11/11/2014 - "However, proteasome inhibitors have not proved effective in treating other cancers, and this has called into question the general applicability of this approach. "
11/01/2014 - "The improved inhibition potency and selectivity of this new α-keto phenylamide makes it a promising candidate for targeting a wider range of tumor subtypes than commercially available proteasome inhibitors and presents a new candidate for future studies."
11/01/2002 - "Phase II and III clinical trials of proteasome inhibitors in treating various tumors have shown promising results, and the side-effects of these drugs are tolerable. "

01/01/2020 - "Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. "
04/03/2018 - "Our studies will support a more personalized therapeutic approach in hematological malignancies treated with proteasome inhibitors."
01/01/2015 - "This review summarizes the current status of the molecular mechanisms underlying resistance to proteasome inhibitors that emerged in preclinical therapeutic studies, and discusses these findings in the clinical perspective of novel therapeutic modalities of hematological malignancies. "
09/28/2009 - "Growing evidence from translational research and clinical trials proved the effectiveness of proteasome inhibitors (PIs) in treating several types of hematological malignancies. "
01/01/2020 - "Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. "

01/01/2006 - "Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas."
12/01/2021 - "Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma."
06/01/2012 - "Proteasome inhibitors in mantle cell lymphoma."
09/20/2022 - "This led to the development and approval of first- and second-generation proteasome inhibitors (PIs), which have improved outcomes for patients with multiple myeloma and mantle cell lymphoma. "
01/01/2020 - "Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma."

02/01/2011 - "proteasome inhibitors) in aggressive lymphomas is being addressed in ongoing clinical trials. "
11/01/2005 - "Herein, some of the biologic rationale for using proteasome inhibitors in lymphoma as well as some of the clinical data from these promising studies are discussed."
01/01/2022 - "PDCD4 downregulation was mediated by proteasomal degradation as it was inhibited by proteasome inhibitors in both primary CLL cells and B-lymphoma cell lines. "
06/01/2015 - "The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. "
11/01/2011 - "We evaluated the killing effect of this proteasome inhibitor on EBV-associated T lymphoma cells and NK lymphoma cells. "